Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32826914&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction #MMPMID32826914
Ejemel M; Li Q; Hou S; Schiller ZA; Tree JA; Wallace A; Amcheslavsky A; Kurt Yilmaz N; Buttigieg KR; Elmore MJ; Godwin K; Coombes N; Toomey JR; Schneider R; Ramchetty AS; Close BJ; Chen DY; Conway HL; Saeed M; Ganesa C; Carroll MW; Cavacini LA; Klempner MS; Schiffer CA; Wang Y
Nat Commun 2020[Aug]; 11 (1): 4198 PMID32826914show ga
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.
free
free
free
Nat+Commun 2020 ; 11 (1): 4198
